Vitamin K Phylloquinone Coagulation: Complete Study Guide

Q: Why is vitamin K called a fat-soluble vitamin and what does this mean clinically?

Vitamin K is fat-soluble because it dissolves in lipids and requires dietary fat for absorption in the small intestine. Clinically, this means patients need adequate fat intake to absorb vitamin K properly. Conditions affecting fat absorption cause vitamin K deficiency despite adequate dietary intake. These include celiac disease, cystic fibrosis, and bile duct obstruction. Medications like orlistat or cholestyramine that interfere with fat absorption impair vitamin K bioavailability. This contrasts with water-soluble vitamins that are more readily absorbed and less dependent on dietary fat. Malnourished patients with fat malabsorption are at higher risk for vitamin K deficiency and bleeding complications, particularly in hospital settings.

Q: What is the difference between vitamin K1 (phylloquinone) and vitamin K2 (menaquinone)?

Phylloquinone (Vitamin K1) is synthesized by plants and comprises approximately 90% of dietary vitamin K intake. It is found primarily in leafy green vegetables. Menaquinone (Vitamin K2) is synthesized by bacteria, including those in the human gut, and is found in fermented foods and some animal products. Both function as cofactors for gamma-carboxylation of clotting factors, but phylloquinone has faster onset of action. Phylloquinone is the preferred therapeutic form for treating vitamin K deficiency. Recent research suggests vitamin K2 may have advantages for bone and cardiovascular health due to differential protein targeting. However, clinical evidence remains limited. For standard coagulation management and deficiency treatment, phylloquinone is the standard of care in medical and nursing practice.

Q: How does vitamin K interact with warfarin and why is monitoring important?

Vitamin K directly antagonizes warfarin's anticoagulant mechanism by serving as a substrate for the enzyme that warfarin inhibits. Warfarin blocks vitamin K epoxide reductase, preventing vitamin K recycling and reducing gamma-carboxylation of clotting factors. When patients take vitamin K, this reverses warfarin's effect and reduces anticoagulation. Conversely, vitamin K deficiency potentiates warfarin's effect and increases bleeding risk. This interaction necessitates careful INR monitoring and dietary counseling. Patients should maintain consistent vitamin K intake rather than avoiding it entirely. If vitamin K intake changes significantly, warfarin dosing adjustments may be required. Healthcare providers must educate patients about vitamin K-containing foods and monitor INR every 2-4 weeks when diet changes or medications affecting vitamin K status are introduced.

Q: Why do newborns receive vitamin K prophylaxis and what is the standard dosing?

Newborns receive vitamin K prophylaxis because of vitamin K deficiency disease, a serious bleeding disorder. The placenta does not efficiently transfer vitamin K from mother to fetus, leaving newborns with extremely low vitamin K stores. Additionally, newborn intestinal bacterial colonization has not yet occurred, preventing endogenous vitamin K synthesis. Newborns also have immature livers with reduced capacity for vitamin K-dependent clotting factor synthesis. These factors combine to create severe deficiency risk in the first days to weeks of life, potentially causing intracranial or gastrointestinal bleeding. Standard prophylaxis is a single intramuscular injection of 0.5-1 mg phylloquinone administered within one hour of birth. This prevents vitamin K deficiency bleeding in 95-98% of cases. Some protocols include additional oral doses at 2-4 weeks for further protection. This simple, inexpensive intervention prevents serious morbidity and mortality and is now standard practice in developed countries.

By FluentFlash Research Team·Updated 2026-04-30

Phylloquinone (Vitamin K1) is essential for blood clotting and bone health. This fat-soluble vitamin activates clotting factors II, VII, IX, and X through a process called gamma-carboxylation. Deficiency can cause serious bleeding disorders, making it critical knowledge for pharmacy and nursing students.

You'll master phylloquinone's biochemistry, physiological roles, therapeutic uses, and dangerous drug interactions. This guide covers everything healthcare professionals need to know to manage vitamin K in clinical practice.

Key Takeaways

•Phylloquinone activates clotting factors II, VII, IX, and X through gamma-carboxylation, making it absolutely critical for normal blood coagulation
•Vitamin K is fat-soluble and requires dietary fat for absorption; malabsorption disorders, antibiotics, and medications affecting fat absorption significantly increase deficiency risk
•Dark leafy green vegetables are the primary dietary source; one serving of kale or spinach provides multiple times the daily recommended intake
•Prolonged PT/INR is the key laboratory finding in vitamin K deficiency; clinical bleeding ranges from mild bruising to life-threatening intracranial hemorrhage
•Warfarin directly antagonizes vitamin K function; patients require consistent dietary vitamin K intake and careful INR monitoring to prevent complications
•Intravenous phylloquinone corrects coagulation abnormalities within 12-24 hours and is the treatment choice for vitamin K deficiency bleeding; newborn prophylaxis prevents serious hemorrhagic disease

What is Phylloquinone and Its Role in Coagulation

Phylloquinone (Vitamin K1) is a fat-soluble vitamin synthesized by plants. It serves as a cofactor for vitamin K-dependent carboxylase, an enzyme that modifies coagulation proteins. This modification is absolutely critical for blood clot formation.

The Four Vitamin K-Dependent Clotting Factors

The body requires four key clotting factors to work properly:

Factor II (prothrombin)
Factor VII
Factor IX
Factor X

Without proper gamma-carboxylation, these factors cannot bind calcium ions, which prevents them from participating in the coagulation cascade. This process occurs primarily in the liver.

Beyond Blood Clotting

Phylloquinone also activates osteocalcin, a protein crucial for bone mineralization. The vitamin is absorbed in the small intestine with dietary fat and stored primarily in the liver. The body has limited storage capacity, so regular dietary intake is necessary.

Vitamin K deficiency develops quickly compared to other fat-soluble vitamins. Deficiency can appear within two to three weeks of inadequate intake. Understanding this mechanism is essential because many medications interfere with vitamin K and can cause serious bleeding complications.

Dietary Sources and Absorption of Vitamin K Phylloquinone

Phylloquinone is abundant in dark leafy green vegetables. A single serving of cooked kale provides 500-600 micrograms of vitamin K, far exceeding the daily recommendation of 90 micrograms for women and 120 micrograms for men.

Best Dietary Sources

Kale, spinach, collard greens
Broccoli and Brussels sprouts
Cabbage, asparagus, green beans
Tea and vegetable oils

How the Body Absorbs Vitamin K

Vitamin K absorption is complex and depends on several factors. Because it is fat-soluble, vitamin K requires dietary fat for optimal absorption in the small intestine. The process requires bile salts and pancreatic lipase for efficient uptake. Approximately 40-60% of dietary phylloquinone is typically absorbed, though this varies based on fat intake and intestinal health.

Absorption Risk Factors

Patients with malabsorption disorders have higher deficiency risk. These include cystic fibrosis, celiac disease, and inflammatory bowel disease. Antibiotics reduce bacterial vitamin K synthesis, potentially causing deficiency in vulnerable populations. Consuming phylloquinone with olive oil or other dietary fats enhances bioavailability. Healthcare students must understand these absorption factors because they directly impact deficiency risk assessment and patient counseling.

Vitamin K Deficiency: Clinical Presentation and Laboratory Assessment

Vitamin K deficiency presents with abnormal bleeding that ranges from minor bruising to severe intracranial bleeding. The classic sign is prolonged prothrombin time (PT), which measures factors II, VII, and X. Platelet count remains normal in isolated vitamin K deficiency, helping distinguish it from other blood disorders.

Vitamin K Deficiency in Newborns

Vitamin K deficiency disease (formerly called hemorrhagic disease of the newborn) can cause serious intracranial bleeding. This occurs because vitamin K does not cross the placenta efficiently. Newborn intestinal colonization with vitamin K-producing bacteria has not yet occurred, so prophylactic intramuscular vitamin K is administered immediately after birth.

How Adults Develop Deficiency

Adults develop deficiency through several mechanisms:

Prolonged antibiotic therapy that destroys gut flora
Malabsorption disorders
Liver disease impairing vitamin K-dependent protein synthesis
Dietary deficiency

Certain medications, particularly warfarin and coumarin anticoagulants, inhibit vitamin K recycling and create functional deficiency. Laboratory assessment includes PT/INR (international normalized ratio), which is highly sensitive for vitamin K deficiency. Assessment of specific clotting factor levels identifies which vitamin K-dependent factors are depleted. Liver function tests help determine whether the problem is vitamin K deficiency versus hepatic failure.

Therapeutic Uses and Vitamin K Supplementation Strategies

Phylloquinone (Vitamin K1) is the preferred form for treating vitamin K deficiency because of faster onset of action. Typical dosing ranges from 10-25 mg daily for oral replacement in deficiency states, though dosing varies based on severity and clinical context.

Routes of Administration and Dosing

Vitamin K can be given through multiple routes, each with different benefits:

Oral: standard for chronic replacement
Intramuscular: faster action than oral
Intravenous: fastest correction, typically within 12-24 hours

IV administration carries a small risk of anaphylaxis and requires careful, slow administration. Standard dosing for acute hemorrhage is 2.5-10 mg IV slowly.

Warfarin Management

When patients taking warfarin show excessive anticoagulation (elevated INR), vitamin K can reverse this effect. Lower doses (1-2.5 mg) are preferred for minor elevation to avoid complete warfarin reversal. Higher doses (10 mg) may be used for severe bleeding. Fresh frozen plasma or prothrombin complex concentrates may be required alongside vitamin K for life-threatening hemorrhage.

Emerging Therapeutic Uses

Vitamin K supplementation is increasingly studied for bone health and cardiovascular disease prevention. Osteocalcin and matrix Gla protein, both vitamin K-dependent proteins, play roles in bone mineralization and vascular calcification prevention. Patients with chronic malabsorption disorders often require long-term vitamin K supplementation.

Drug Interactions and Clinical Monitoring Considerations

Vitamin K has significant interactions with multiple medications. Understanding these interactions prevents serious bleeding or thrombotic complications.

Warfarin and Anticoagulants

Warfarin and coumarin derivatives directly antagonize vitamin K by inhibiting the vitamin K epoxide reductase enzyme complex. This prevents vitamin K recycling and reduces gamma-carboxylation of clotting factors. Patients on warfarin must maintain consistent vitamin K intake because large increases or decreases destabilize INR.

Sudden dietary changes, such as consuming large amounts of leafy greens, require INR monitoring and possible warfarin dose adjustments. Patients should maintain vitamin K intake rather than avoiding it entirely.

Other Medication Interactions

Antibiotics decrease vitamin K production by eliminating intestinal flora, increasing deficiency risk. Cholestyramine and mineral oil bind fat-soluble vitamins and impair absorption. Some anticonvulsants (phenytoin, phenobarbital) increase vitamin K metabolism through enzyme induction and can cause deficiency despite normal intake.

Orlistat inhibits fat absorption and reduces vitamin K bioavailability. Systemic corticosteroids may increase deficiency risk through multiple mechanisms. Gemfibrozil and salicylates enhance warfarin effects independently.

Clinical Monitoring Requirements

Monitor INR more frequently when vitamin K intake changes or medications affecting vitamin K status are introduced. Check INR every 2-4 weeks during these periods. Counsel patients about vitamin K-containing foods and maintain consistent intake.

Master Vitamin K Phylloquinone and Coagulation

Strengthen your understanding of vitamin K's mechanisms, clinical applications, and critical drug interactions with interactive flashcards designed for pharmacology and nursing students. Study efficiently with spaced repetition and ensure you're ready for exams and clinical practice.

Create Free Flashcards

Frequently Asked Questions

Why is vitamin K called a fat-soluble vitamin and what does this mean clinically?

Vitamin K is fat-soluble because it dissolves in lipids and requires dietary fat for absorption in the small intestine. Clinically, this means patients need adequate fat intake to absorb vitamin K properly.

Conditions affecting fat absorption cause vitamin K deficiency despite adequate dietary intake. These include celiac disease, cystic fibrosis, and bile duct obstruction. Medications like orlistat or cholestyramine that interfere with fat absorption impair vitamin K bioavailability.

This contrasts with water-soluble vitamins that are more readily absorbed and less dependent on dietary fat. Malnourished patients with fat malabsorption are at higher risk for vitamin K deficiency and bleeding complications, particularly in hospital settings.

What is the difference between vitamin K1 (phylloquinone) and vitamin K2 (menaquinone)?

Phylloquinone (Vitamin K1) is synthesized by plants and comprises approximately 90% of dietary vitamin K intake. It is found primarily in leafy green vegetables. Menaquinone (Vitamin K2) is synthesized by bacteria, including those in the human gut, and is found in fermented foods and some animal products.

Both function as cofactors for gamma-carboxylation of clotting factors, but phylloquinone has faster onset of action. Phylloquinone is the preferred therapeutic form for treating vitamin K deficiency.

Recent research suggests vitamin K2 may have advantages for bone and cardiovascular health due to differential protein targeting. However, clinical evidence remains limited. For standard coagulation management and deficiency treatment, phylloquinone is the standard of care in medical and nursing practice.

How does vitamin K interact with warfarin and why is monitoring important?

Vitamin K directly antagonizes warfarin's anticoagulant mechanism by serving as a substrate for the enzyme that warfarin inhibits. Warfarin blocks vitamin K epoxide reductase, preventing vitamin K recycling and reducing gamma-carboxylation of clotting factors.

When patients take vitamin K, this reverses warfarin's effect and reduces anticoagulation. Conversely, vitamin K deficiency potentiates warfarin's effect and increases bleeding risk. This interaction necessitates careful INR monitoring and dietary counseling.

Patients should maintain consistent vitamin K intake rather than avoiding it entirely. If vitamin K intake changes significantly, warfarin dosing adjustments may be required. Healthcare providers must educate patients about vitamin K-containing foods and monitor INR every 2-4 weeks when diet changes or medications affecting vitamin K status are introduced.

What causes vitamin K deficiency in hospitalized patients and how is it prevented?

Hospitalized patients develop vitamin K deficiency through multiple mechanisms. Prolonged antibiotic therapy destroys gut flora responsible for menaquinone synthesis. Reduced oral intake due to NPO (nothing by mouth) status or limited dietary variety decreases dietary phylloquinone. Malabsorption from diarrhea impairs absorption. Some medications increase vitamin K metabolism.

Prevention strategies include prophylactic vitamin K supplementation in high-risk patients, particularly those on prolonged antibiotics. Maintain oral intake when possible and choose antibiotics with less impact on normal flora. Monitor PT/INR regularly to identify early deficiency before clinical bleeding occurs.

Some hospitals administer prophylactic vitamin K to high-risk patients. Understanding these risk factors allows clinicians to implement preventive measures and identify deficiency early in hospitalized populations.

Why do newborns receive vitamin K prophylaxis and what is the standard dosing?

Newborns receive vitamin K prophylaxis because of vitamin K deficiency disease, a serious bleeding disorder. The placenta does not efficiently transfer vitamin K from mother to fetus, leaving newborns with extremely low vitamin K stores. Additionally, newborn intestinal bacterial colonization has not yet occurred, preventing endogenous vitamin K synthesis. Newborns also have immature livers with reduced capacity for vitamin K-dependent clotting factor synthesis.

These factors combine to create severe deficiency risk in the first days to weeks of life, potentially causing intracranial or gastrointestinal bleeding. Standard prophylaxis is a single intramuscular injection of 0.5-1 mg phylloquinone administered within one hour of birth. This prevents vitamin K deficiency bleeding in 95-98% of cases.

Some protocols include additional oral doses at 2-4 weeks for further protection. This simple, inexpensive intervention prevents serious morbidity and mortality and is now standard practice in developed countries.